Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Medtronic
Johnson and Johnson
Accenture
Boehringer Ingelheim
US Army
Farmers Insurance
Dow
Cerilliant
McKesson

Generated: January 21, 2018

DrugPatentWatch Database Preview

DUAVEE Drug Profile

« Back to Dashboard

When do Duavee patents expire, and when can generic versions of Duavee launch?

Duavee is a drug marketed by Wyeth Pharms Pfizer and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-four patent family members in forty countries.

The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.
Summary for DUAVEE
International Patents:64
US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Clinical Trials: 6
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DUAVEE at DailyMed
Drug patent expirations by year for DUAVEE

US Patents and Regulatory Information for DUAVEE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Pfizer DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Wyeth Pharms Pfizer DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Wyeth Pharms Pfizer DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Wyeth Pharms Pfizer DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Wyeth Pharms Pfizer DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Wyeth Pharms Pfizer DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Wyeth Pharms Pfizer DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for DUAVEE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,326,367 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents ➤ Subscribe
7,132,417 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents ➤ Subscribe
6,127,404 Tissue selective compounds in the treatment of endometrial proliferation ➤ Subscribe
6,924,281 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents ➤ Subscribe
7,247,624 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents ➤ Subscribe
7,449,455 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents ➤ Subscribe
6,225,308 Tissue selective compounds in the treatment of prostate cancer or benign prostate hypertrophy ➤ Subscribe
6,787,538 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents ➤ Subscribe
6,291,451 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents ➤ Subscribe
6,232,307 Tissue selective compounds in the treatment of ovarian cancer ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for DUAVEE

Supplementary Protection Certificates for DUAVEE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
4 Finland ➤ Subscribe
2009007 Lithuania ➤ Subscribe PRODUCT NAME: BAZEDOXIFENUM; REGISTRATION NO/DATE: EU/1/09/511/001 - EU/1/09/511/004 20090417
C/GB09/045 United Kingdom ➤ Subscribe PRODUCT NAME: BAZEDOXIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/09/511/001 20090417; UK EU/1/09/511/002 20090417; UK EU/1/09/511/003 20090417; UK EU/1/09/511/004 20090417
0416 Netherlands ➤ Subscribe 300416, 20170415, EXPIRES: 20220414
09/028 Ireland ➤ Subscribe PRODUCT NAME: BAZEDOXIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/09/511/001-004 20090417
2009 00035 Denmark ➤ Subscribe
C0048 France ➤ Subscribe PRODUCT NAME: BAZEDOXIFENE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/09/511/001 DU 20090417; REGISTRATION NO/DATE AT EEC: EU/1/09/511/001-004 DU 20090417
608 Luxembourg ➤ Subscribe 91608, EXPIRES: 20220415
2009007,C0802183 Lithuania ➤ Subscribe PRODUCT NAME: BAZEDOXIFENUM; REGISTRATION NO/DATE: EU/1/09/511/001 - EU/1/09/511/004 20090417
0802183/01 Switzerland ➤ Subscribe PRODUCT NAME: BAZEDOXIFEN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58732 12.01.2010
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Queensland Health
Cantor Fitzgerald
Argus Health
Colorcon
Healthtrust
Cerilliant
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot